GUJARAT THEMIS BIOSYN LTD.

Gujarat Themis Biosyn Ltd has announced a Board of Directors meeting scheduled for September 1, 2026. The primary agenda is to consider and approve raising funds through the issuance of equity shares and/or convertible warrants via a preferential issue on a private placement basis. This move is subject to necessary approvals, including shareholder and stock exchange consent. Concurrently, the company has implemented a trading window closure for designated persons and their immediate relatives, effective until 48 hours after the meeting's outcome is announced, to prevent insider trading.

Gujarat Themis Biosyn Ltd has submitted its audited financial statements for the quarter and year ended March 31, 2026, as per Regulation 30 (LODR). These statements, along with the auditor's report, were previously considered and approved by the Board of Directors on May 25, 2026. The financial statements provide a true and fair view of the company's affairs in conformity with Indian Accounting Standards. Key audit matters highlighted include revenue recognition and capital work-in-progress/Property Plant and Equipment. The statements are subject to adoption by shareholders at the upcoming Annual General Meeting and are available on the company's website.

Gujarat Themis Biosyn Limited announced that its shareholders have approved an amendment to the company's Articles of Association via a special resolution passed through postal ballot on August 22, 2026. The amendment involves deleting specific wording from Article 13(1) Clause (c) related to the determination of share prices by a registered valuer. The revised clause now permits transactions for cash or consideration other than cash without the requirement of a valuation report.

Gujarat Themis Biosyn Limited announced that its shareholders, through a special resolution passed at an Extraordinary General Meeting on August 22, 2026, have approved an amendment to the company's Articles of Association. Specifically, Clause 13(1)(c) has been amended by deleting the requirement for a valuation report from a registered valuer when determining the price of shares. The amended clause now broadly permits transactions for cash or consideration other than cash, irrespective of whether the parties involved are already mentioned in previous clauses.

Gujarat Themis Biosyn's Q1 FY27 consolidated results (identical to standalone this quarter) show revenue of ₹43.79 Cr, up 22.1% YoY from ₹35.87 Cr, and PAT of ₹11.07 Cr, up 22.1% YoY from ₹9.06 Cr; EPS rose to ₹1.02 from ₹0.83. Sequentially the quarter was flat — revenue down 1.0% and PAT up 1.6% versus Q4 FY26. No exceptional items featured in either period. There is no analyst/street consensus coverage identifiable for this micro-cap (paid-up capital ₹10.90 Cr) and no formal management guidance on record, so the print cannot be benchmarked against external expectations; no separate management commentary or press release was available for this filing beyond the regulatory results statement. Operating margin (EBITDA/revenue) expanded sharply to 47.5% from 38.8% a year ago (+870 bps), as revenue growth of 22.1% outran total expense growth of 19.7%. Much of the expense relief came from a bigger favourable swing in finished-goods/work-in-progress inventory build (₹-3.91 Cr this quarter versus just ₹-0.20 Cr YoY), which lowers the cost of goods recognised in the P&L, while employee costs rose faster than revenue at 51.7% YoY to ₹4.72 Cr. Net profit margin, however, was nearly flat at 25.2% versus 25.1% YoY — the operating-line gain was largely absorbed below the line by finance costs jumping to ₹1.79 Cr from just ₹0.04 Cr YoY and depreciation rising to ₹3.97 Cr from ₹2.03 Cr YoY, consistent with new capacity/assets coming onto the books and additional borrowing. This is the company's first quarter reporting consolidated numbers, following incorporation of two wholly-owned subsidiaries, Themis Biosyn Japan and Themis Biosyn Ireland, both yet to commence operations and contributing nil revenue, profit and comprehensive income this quarter. Alongside the results, the company has called an EGM for August 22 to approve related-party transactions, and shareholding records this quarter show the promoter group releasing 25.45 lakh shares (1.51% of holding) from pledge while separately creating a fresh indirect encumbrance covering 47.02% of the promoter stake; promoter Sachin D Patel separately acquired 5.23 lakh shares. With finance costs and depreciation now running near ₹1.8 Cr and ₹4.0 Cr a quarter respectively, net margin is likely to keep tracking revenue growth rather than the wider EBITDA-margin gains unless the borrowing/asset base stabilizes. The Aug 22 EGM outcome on related-party transactions and whether the Japan/Ireland subsidiaries begin contributing to consolidated financials are the near-term items to track.

Sachin D Patel has acquired 5,23,560 equity shares of Gujarat Themis Biosyn Limited, representing 0.48% of the diluted share capital. The acquisition was an inter-se transfer among the promoter and promoter group, with Pharmaceutical Business Group India Limited as the transferor. This transaction was executed at a price of ₹382 per share. The acquirer has utilized the exemption under Regulation 10(1)(a)(iI) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the transfer is among persons named as promoters. Prior intimation of the inter-se transfer was made on July 14, 2026, and the disclosure was filed within the stipulated timeline.

Gujarat Themis Biosyn Limited has announced an Extraordinary General Meeting (EGM) scheduled for August 22, 2026, at 12:00 PM IST. The EGM will be held at the registered office of Themis Medicare Limited in Vapi, Gujarat. The primary purpose of the meeting is to transact ordinary and special businesses, including seeking member approval for material related party transactions with promoter/promoter group entities. This includes potential borrowing, conversion of outstanding debt into equity, and amendments to the Articles of Association. The notice for the EGM is being circulated to shareholders on July 31, 2026, and is also available on the company's website and the e-voting platform.

Gujarat Themis Biosyn Ltd has announced that its Board of Directors will convene on August 7, 2026. The primary agenda item is to consider and approve the Un-Audited Financial Results for the quarter ending June 30, 2026, along with the Auditor's Limited Review Reports. Additionally, the company has informed its 'Designated Persons' about the closure of the Trading Window from July 1, 2026, until 48 hours after the financial results are published, in compliance with SEBI's Insider Trading Regulations.

Gujarat Themis Biosyn Limited (GTBL) has reported an indirect encumbrance on 47.02% of its equity share capital, held by its promoter group entity, Pharmaceutical Business Group (India) Limited (PBGIL). This encumbrance arises from a pledge of 25,24,245 equity shares (51% of PBGIL's capital) and a non-disposal undertaking over 21,57,855 equity shares (47.98% of PBGIL's capital) by Vividhmargi Investments Private Limited (VIPL) in favor of CTL Trusteeship Limited. The encumbrance is in connection with debentures issued by PBGIL. This disclosure is made under SEBI (SAST) Regulations, 2011.

Gujarat Themis Biosyn Limited (GTBL) has disclosed an indirect encumbrance on 47.02% of its equity share capital, held by its promoter group entity, Pharmaceutical Business Group (India) Limited (PBGIL). This encumbrance arises from a pledge of 51% and a non-disposal undertaking over 47.98% of PBGIL's shares by Vividhmargi Investments Private Limited (VIPL) in favor of CTL Trusteeship Limited. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, following the creation of these instruments on June 29, 2026, in connection with a debenture trust deed.